GSK's Jemperli meets main goal in mid-stage rectal cancer trial

GSK said its cancer drug Jemperli met the primary endpoint in a mid-stage trial in locally advanced rectal cancer, with a clinically significant share of patients showing no detectable cancer for ≥1 year after treatment. The positive efficacy signal supports continued development momentum, though it is not yet confirmed as a late-stage registrational outcome.

Analysis

GSK said its cancer drug Jemperli met the primary endpoint in a mid-stage trial in locally advanced rectal cancer, with a clinically significant share of patients showing no detectable cancer for ≥1 year after treatment. The positive efficacy signal supports continued development momentum, though it is not yet confirmed as a late-stage registrational outcome.